Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956783 | 1.00 | CNR2 (0.44) | CNR2CNR1PDK2ENPP3ACHE | |
| SCHEMBL5156114 | 0.84 | BRD9 (0.40) | CNR2CNR1PDK2ACHEMAPT | |
| SCHEMBL29928761 | 0.82 | MGLL (0.53) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL5124813 | 0.82 | MGLL (0.53) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL29825499 | 0.82 | MGLL (0.53) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL26702092 | 0.81 | HSD17B10 (0.42) | CNR2CNR1PDK2ACHENPC1 | |
| SCHEMBL28414965 | 0.81 | ACHE (0.55) | CNR2CNR1PDK2ENPP3ACHE | |
| SCHEMBL7003183 | 0.81 | ESR2 (0.46) | PDK2ACHESMN1; SMN2HPGDMAPT | |
| SCHEMBL31601135 | 0.81 | ESR2 (0.46) | PDK2ACHESMN1; SMN2HPGDMAPT | |
| SCHEMBL6379712 | 0.81 | HSD17B1 (0.48) | MAP4K4PDGFRBPIM1FGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115959993-B | Synthesis method of 2-aryl propionic acid compound | 山东中医药大学 | 2025-01-07 | — | — | CN | claimed |
| CN-111303150-A | High-efficiency narrow-half-peak-width aggregation state luminescent material | 苏州大学 | 2020-06-19 | — | — | CN | claimed |
| CN-114262330-B | Fascaplysin derivative, preparation method and application thereof in resisting MRSA | 宁波大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-111303150-B | High-efficiency narrow-half-peak-width aggregation state luminescent material | 苏州大学 | 2021-10-19 | — | — | CN | disclosed |
| CN-111303150-A | High-efficiency narrow-half-peak-width aggregation state luminescent material | 苏州大学 | 2020-06-19 | — | — | CN | disclosed |
| EP-2021330-B1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2021330-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007130780-A2 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CNR2 31/4885CNR1 33/4885PDK2 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.